Barclays
OBIO icon

Barclays’s Orchestra BioMed OBIO Stock Holding History

Barclays’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$252K Sell
59,342
-35,175
-37% -$150K ﹤0.01% 3555
2025
Q4 		$392K Buy
94,517
+94,516
+9,451,600% +$381K ﹤0.01% 3980
2025
Q3 		$2 Sell
1
-873
-100% -$2.41K ﹤0.01% 5437
2025
Q2 		$2.34K Sell
874
-24,735
-97% -$72.2K ﹤0.01% 5028
2025
Q1 		$110K Sell
25,609
-12,177
-32% -$60.5K ﹤0.01% 4371
2024
Q4 		$151K Buy
37,786
+6,001
+19% +$32.2K ﹤0.01% 4429
2024
Q3 		$163K Buy
31,785
+23,448
+281% +$153K ﹤0.01% 4397
2024
Q2 		$67.9K Sell
8,337
-2,111
-20% -$12.2K ﹤0.01% 4084
2024
Q1 		$55.1K Sell
10,448
-9,693
-48% -$65.7K ﹤0.01% 4598
2023
Q4 		$184K Buy
20,141
+16,988
+539% +$116K ﹤0.01% 4454
2023
Q3 		$27.5K Buy
3,153
+28
+0.9% +$188 ﹤0.01% 4086
2023
Q2 		$21.9K Sell
3,125
-3,829
-55% -$58.1K ﹤0.01% 4119
2023
Q1 		$136K Buy
+6,954
New +$80.5K ﹤0.01% 4011

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Barclays's OBIO Position: Q1 2026 in Review

Barclays reduced its Orchestra BioMed (OBIO) stake by 37% in Q1 2026, selling an estimated $150K and leaving 59,342 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #3555.

Barclays first reported a position in OBIO in Q1 2023 and has held it in 13 quarters since. The position peaked at $392K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Barclays held 59,342 shares of Orchestra BioMed worth $252K as of Q1 2026.
  • Barclays sold 35,175 Orchestra BioMed shares in Q1 2026, an estimated $150K.
  • Orchestra BioMed made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3555 holding.
  • Barclays first reported a position in Orchestra BioMed in Q1 2023 and has held it in 13 quarters since.
  • Barclays's Orchestra BioMed position peaked at $392K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.